OASIS DERMATOLOGY GROUP

Ph: (956) 971 - 0404
www.oasisderm.com

Lichen Sclerosus

Lichen Sclerosus (LS), also referred to as lichen sclerosus et atrophicus, is a chronic dermatologic condition characterized by skin thinning and scarring. The exact etiology of lichen sclerosus remains unknown, though it is believed to involve a combination of autoimmune mechanisms, genetic predisposition, and environmental triggers. The condition predominantly affects the genital and perianal areas but may also involve other areas of the body, with variable severity. The pathophysiology includes inflammation, collagen deposition, and epidermal thinning, which can result in atrophic, hypopigmented plaques with a porcelain white appearance.

Epidemiology and Demographics

Lichen sclerosus typically presents in adult women, with the mean age of onset being approximately 50 years; however, it can also affect men and children. The gender ratio for women to men is approximately 10:1, making it much more common in females. In men, the mean age of onset is earlier, typically around 43 years. While most cases are asymptomatic, the condition can cause significant discomfort, especially in the genital area, where symptoms may include painful urination, dyspareunia (painful intercourse), and erosions. In men, recurrent inflammation and pain of the foreskin can lead to complications such as phimosis, a condition in which the foreskin becomes tight and cannot be retracted over the glans.

Clinical Features

Lichen sclerosus is characterized by the development of white, angular, well-defined papules and plaques that may coalesce into larger patches. These lesions exhibit a shiny, semi-transparent appearance, resembling mother-of-pearl. Common locations for lichen sclerosus include:

- ***Genital skin****:* In women, it typically involves the vulva and perineum, sometimes presenting with a figure-of-eight pattern around the anogenital region. In men, it is primarily localized to the glans and the undersurface of the foreskin.
- ***Non-genital skin****:* Often affects the upper back, neck, axillae, periumbilical area, and ventral wrists.

While asymptomatic in many cases, the condition can be highly symptomatic in the genital area. The lesions may be painful, leading to dyspareunia in women and painful urination. A notable complication is the potential for squamous cell carcinoma (SCC) in the genital lesions, though the risk is considered low overall, risk becomes more elevated in long-standing cases.

Pathophysiology

The precise cause of lichen sclerosus is still not well understood, though it is widely believed to be an autoimmune disorder, with genetic and environmental factors playing a role. T-cell-mediated inflammation is thought to play a key role in the development of the lesions. Autoantibodies targeting the extracellular matrix proteins (ECM-1) of the skin may contribute to the epidermal thinning and collagen deposition seen in this condition. There is also a strong association with autoimmune diseases such as Hashimoto's thyroiditis, vitiligo, and pemphigus vulgaris.

Diagnosis

Lichen sclerosus is primarily diagnosed based on clinical features and patient history, especially in characteristic areas such as the genital skin. A skin biopsy is typically performed when the diagnosis is uncertain or when there is suspicion of malignancy. Histopathological findings include epidermal thinning, loss of rete ridges, and hyperkeratosis. In cases of genital involvement, the risk of squamous cell carcinoma increases, and therefore, regular monitoring and biopsy of suspicious lesions are recommended.

Treatment Options

The treatment of lichen sclerosus focuses on symptom relief and preventing disease progression. Topical corticosteroids are considered the mainstay of treatment, particularly potent or super-potent steroids, which are used to reduce inflammation and promote skin healing. Clobetasol propionate is the most commonly prescribed corticosteroid for lichen sclerosus, and it has been shown to significantly improve symptoms and decrease lesion size.

Treatment for Non-Responsive Cases:

- Hydroxychloroquine, an anti-malarial drug, has been reported to be effective in some cases of refractory lichen sclerosus, particularly in patients with co-existing autoimmune diseases. It is thought to act by modulating the immune response.
- For more severe cases, phototherapy (such as narrowband UVB) or systemic immunosuppressive treatments such as methotrexate, or cyclosporine, may be considered.

Surgical Interventions:

- In cases where phimosis occurs in men, circumcision may be performed. This not only provides symptom relief but can also lead to remission of the disease in the affected area.

Monitoring and Follow-Up:

- Regular monitoring for squamous cell carcinoma is recommended, especially in cases of genital lichen sclerosus. Biopsy of any new or changing lesions is important for early detection of malignancy.

Prognosis

Lichen sclerosus is a chronic condition, and while the disease may be well controlled with treatment, it often requires long-term management. Remission is possible, especially with appropriate use of topical corticosteroids, but genital lesions in particular are prone to recurrence. In severe or untreated cases, scarring and functional impairment can occur. The risk of squamous cell carcinoma in genital lesions is elevated, though the overall risk remains relatively low.

Conclusion

Lichen sclerosus is a chronic skin disorder with significant implications, particularly for genital and perianal involvement. While its precise cause remains elusive, the condition is generally managed with topical corticosteroids. In refractory cases, systemic treatments such as hydroxychloroquine may be necessary. Early diagnosis and appropriate treatment are crucial to preventing complications, including squamous cell carcinoma and scarring. Regular follow-up is essential to monitor for recurrence and potential malignancy.

References

- Lotti, T., Mazzanti, C., & Re, S. (2020). Lichen sclerosus: A review of the clinical features, pathogenesis, and treatment options. *Dermatologic Therapy*, 33(5), e13985. https://doi.org/10.1111/dth.13985
- McGrath, J. A., & Uitto, J. (2020). Lichen sclerosus: A critical review. *Journal of Investigative Dermatology*, 140(9), 1897-1905. https://doi.org/10.1016/j.jid.2020.01.038
- Paus, R., Muller, S., & Tschernig, T. (2019). Lichen sclerosus et atrophicus: Clinical features, pathogenesis, and treatment strategies. *American Journal of Clinical Dermatology*, 20(6), 881-891. https://doi.org/10.1007/s40257-019-00467-2
- Sibbald, R. G., Hovav, A., & Nance, L. (2018). Lichen sclerosus: Diagnostic and therapeutic updates. *Cutis*, 101(6), 455-461.